AU2022297444A1 - Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function - Google Patents

Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function Download PDF

Info

Publication number
AU2022297444A1
AU2022297444A1 AU2022297444A AU2022297444A AU2022297444A1 AU 2022297444 A1 AU2022297444 A1 AU 2022297444A1 AU 2022297444 A AU2022297444 A AU 2022297444A AU 2022297444 A AU2022297444 A AU 2022297444A AU 2022297444 A1 AU2022297444 A1 AU 2022297444A1
Authority
AU
Australia
Prior art keywords
atp
methods
compositions containing
cognitive function
adenosine triphosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022297444A
Other languages
English (en)
Inventor
Shawn Baier
Larry KOLB
John Rathmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsi Usa LLC
Original Assignee
Tsi Usa LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Usa LLC filed Critical Tsi Usa LLC
Publication of AU2022297444A1 publication Critical patent/AU2022297444A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2022297444A 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function Pending AU2022297444A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213378P 2021-06-22 2021-06-22
US63/213,378 2021-06-22
PCT/US2022/034510 WO2022271813A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Publications (1)

Publication Number Publication Date
AU2022297444A1 true AU2022297444A1 (en) 2024-01-18

Family

ID=84544774

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022297444A Pending AU2022297444A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Country Status (12)

Country Link
US (1) US20240299435A1 (https=)
EP (1) EP4358972A4 (https=)
JP (1) JP2024524288A (https=)
CN (1) CN117835985A (https=)
AU (1) AU2022297444A1 (https=)
CA (1) CA3224861A1 (https=)
CL (1) CL2023003882A1 (https=)
CO (1) CO2024000517A2 (https=)
EC (1) ECSP24004256A (https=)
MX (1) MX2024000145A (https=)
PE (1) PE20241617A1 (https=)
WO (1) WO2022271813A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
WO2008001494A1 (en) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients
PH12022550598A1 (en) * 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
US20140044690A1 (en) * 2012-08-08 2014-02-13 University Of South Florida High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
US10092590B2 (en) * 2012-09-10 2018-10-09 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2014106860A2 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
BR112022004108A2 (pt) * 2019-09-05 2022-05-31 Tsi Group Ltd Métodos para aprimorar a absorção gastrointestinal e utilização sistêmica de materiais nutricionais, para aumentar a biodisponibilidade de um material nutricional em um animal e para aprimorar a absorção de um material nutricional em ser humano

Also Published As

Publication number Publication date
JP2024524288A (ja) 2024-07-05
CN117835985A (zh) 2024-04-05
PE20241617A1 (es) 2024-08-07
WO2022271813A1 (en) 2022-12-29
EP4358972A4 (en) 2025-04-16
CA3224861A1 (en) 2022-12-29
CO2024000517A2 (es) 2024-05-10
CL2023003882A1 (es) 2024-07-05
MX2024000145A (es) 2024-03-22
EP4358972A1 (en) 2024-05-01
ECSP24004256A (es) 2024-02-29
US20240299435A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
EP4141007A4 (en) ANTIVIRAL USE OF A NUCLEOSIDE ANALOGUE OR A COMBINATION FORMULATION CONTAINING A NUCLEOSIDE ANALOGUE
EP4319763A4 (en) MODIFIED NUCLEOSIDES AND NUCLEOTIDE ANALOGUES AS ANTIVIRAL AGENT FOR CORONAVIRUS AND OTHER VIRUSES
WO2024039901A3 (en) Cdk2 degraders and uses thereof
GEAP202215528A (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
PH12023500023A1 (en) Cdk2 degraders and uses thereof
WO2023049790A3 (en) Mdm2 degraders and uses thereof
GB2622114B (en) Experimental system for simulating high or low temperature vacuum environment of planet
EP4090332A4 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES COMPOSITIONS AND USES THEREOF
HUE073427T2 (hu) Adenozin-trifoszfátot (ATP) tartalmazó készítmények és alkalmazási eljárások
AU2022219942A9 (en) Methods and compositions for cryopreservation of immune cells
AU2022297444A1 (en) Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function
HK40103878A (en) Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function
SG11202007228WA (en) Method for suppressing discoloration of external composition containing adenosine phosphate and tranexamic acid
CA3265884A1 (en) TRYPTAMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
EP4294405A4 (en) COMPOSITIONS AND COMPOUNDS FOR CO-ADMINISTRATION OF URIDINE AND KETOLEUCINE
MX2021009278A (es) Nucleosidos antivirales y derivados de estos.
HK40108644A (en) Polymerases, compositions, and methods of use
HK40106755A (en) Nucleosides and nucleotides analogs as antiviral agents
HK40103439A (en) Inhibitors of atp synthase - cosmetic and therapeutic uses
HK40085814A (en) Compositions for translation and methods of use thereof
HK40105553A (en) Compositions and compounds for co-delivery of uridine and ketoleucine
AU2019903184A0 (en) Nucleoside compounds and methods of synthesis and use thereof
CA3267979A1 (en) Novel stabilized nucleoside phosphates and analogues thereof
HK40130554A (zh) 用於改性释放米诺地尔的组合物和使用方法
HK40096898A (en) Analogs of cddo-2p-im and cddo-3p-im